Patient-Derived Models

Explore the utility of patient-derived models, including organoids, patient-derived xenografts (PDX), and patient-derived tumor organoids (PDTO), for studying cancer stem cell biology and drug screening. This track highlights the advantages and limitations of different patient-derived model systems, offering insights into their relevance for understanding tumor heterogeneity, drug response, and therapeutic resistance. Discover how patient-derived models are shaping preclinical drug development and personalized medicine approaches in oncology, offering new opportunities for translational research and therapeutic innovation.

    Related Conference of Patient-Derived Models

    February 05-06, 2026

    11th World Conference on Breast and Cervical Cancer

    Paris, France
    February 19-20, 2026

    7th Cancer Diagnostics & Treatment Conference

    Miami, USA
    February 19-20, 2026

    8th International Conference on Women Oncology

    Miami, USA
    March 09-10, 2026

    4th World Congress on Oral Cancer

    Singapore City, Singapore
    March 30-31, 2026

    26th World Congress on Cancer and Diagnostics

    London, UK
    June 15-16, 2026

    10th Global Meeting on Oncology and Radiology

    Paris, France
    June 22-23, 2026

    16th World Congress on Breast Cancer

    Dubai, UAE
    June 23-24, 2026

    27th World Congress on Cancer Summit

    Paris, France
    July 27-28, 2026

    6th World Congress on Breast Cancer

    Rome, Italy
    September 28-29, 2026

    36th Experts Meet On Cancer Research & Therapy

    Aix-en-Provence, France
    September 29-30, 2026

    5th Experts Meeting on Cancer Medicine, Radiology & Treatment

    Aix-en-Provence, France

    Patient-Derived Models Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in